Symptomatic versus Endoscopic approach for the Diagnosis and Initial treatment of Gastroesophageal Reflux Disease using GerdQ

AstraZeneca AS0 个研究点目标入组 348 人开始时间: 2008年12月12日最近更新: 2012年3月19日

试验速览

暂无简介。

•1.Provision of informed consent prior to any study specific procedures
•2.Female or male aged 18 years or more
•3.Symptoms suggestive of typical GERD (heartburn or acid regurgitation as predominant symptoms) referred to or followed up by gastroenterologist
•4.Understand and complete the questionnaires.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Major health condition that precludes participation, as judged by the investigator
•2.Alarm symptoms defined as unintentional weight loss, severe or progressive dysphagia, and upper GI bleeding
•3.Use of more than 2 doses per week of PPI and H2RA, and use of more than one daily dose of antacids within 2 weeks prior to Visit 1
•4.Endoscopic and/or pH-metry examination within 1 year prior to Visit 1
•5.Previous upper GI surgery
•6.Participation in any clinical study within the defined treatment period
•7.Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

发起方

AstraZeneca AS